Agenus Advances Cancer Drugs with $20M Manufacturing Milestone

LEXINGTON, MA - March 10, 2026 - Immuno-oncology firm Agenus Inc. has initiated a critical phase in its journey toward commercializing its flagship cancer therapies, triggering a $20 million payment from its strategic partner, Zydus Lifesciences, that Agenus will use strictly for manufacturing expenses that Zydus will provide.

The payment represents the first major operational milestone under a comprehensive collaboration forged between Agenus and Zydus. It specifically funds contracted work orders for essential chemistry, manufacturing, and controls (CMC) activities. These processes are fundamental for ensuring consistent, high-quality production of biologic drugs and are a prerequisite for submitting Biologics License Applications (BLA) in the U.S. and Marketing Authorization Applications (MAA) in Europe.

This development is not merely a procedural step but a strategic push to build inventory, satisfy stringent regulatory requirements, and prepare for a potential global launch. It directly addresses the anticipated need for BOT and BAL, which are currently being administered through clinical trials and expanding early access programs worldwide.

“This milestone reflects our commitment to progressing BOT and BAL to regulatory approval readiness, and to support our ongoing clinical development and paid compassionate access program needs,” said Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus, in a statement. “It is essential that we proactively align manufacturing capacity with anticipated demand.”

A Strategic Partnership Takes Root

Today's announcement marks the first significant operational activity between Agenus and Zylidac Bio LLC, the U.S.-based biologics manufacturing subsidiary established by Zydus. The foundation for this work was laid through a multifaceted strategic agreement announced in June 2025 and finalized in January 2026.

Under the original terms, Agenus transferred its biologics manufacturing facilities in Emeryville and Berkeley, California, to Zydus in a deal that infused Agenus with $75 million in upfront cash. The agreement also included a strategic equity investment from Zydus and up to $50 million in future contingent payments tied to production orders - the first $20 million of which has now been triggered.

For Agenus, the deal was a masterstroke of financial strategy, allowing it to monetize physical assets and convert a fixed cost base into a variable, on-demand manufacturing service. This provides access to dedicated, long-term U.S.-based production capacity without the associated capital expenditure and operational overhead. For Zydus, the acquisition provided a turnkey entry into the U.S. biologics contract development and manufacturing (CDMO) market, with Agenus secured as its flagship first customer.

De-Risking the Path to Market

The ramp-up in manufacturing is a critical de-risking event for Agenus and its stakeholders. In the high-stakes world of drug development, a brilliant clinical breakthrough can be stymied by an inability to produce the therapy at commercial scale. By initiating these CMC and production activities with Zydus well ahead of potential approvals, Agenus is mitigating supply chain risks and ensuring market readiness.

The work will not only support the global BATTMAN Phase 3 trial in refractory microsatellite-stable (MSS) colorectal cancer but also build upon existing inventory. This stockpile is crucial for serving the French early access (AAC) program, where BOT+BAL is fully reimbursed for eligible patients, and paid named-patient programs in other countries where the therapy is available prior to formal marketing authorization.

Botensilimab, an advanced anti-CTLA-4 antibody, and balstilimab, a PD-1 inhibitor, have shown significant promise when used in combination, particularly in “cold” tumors that have historically failed to respond to immunotherapy. Clinical data has demonstrated encouraging survival rates in difficult-to-treat cancers, including MSS colorectal cancer, fueling significant interest from clinicians and patients globally.

Capital Discipline in a Cash-Intensive Industry

The structure of the Zydus collaboration highlights Agenus's focus on financial prudence. The contingent payment model allows the company to fund essential manufacturing activities as needed, directly linking expenditures to progress and demand. This preserves the company's cash position for its core focus: research, clinical development, and regulatory advancement.

“Our partnership with Zydus enables us to scale thoughtfully while maintaining capital discipline,” Armen noted in his statement. This approach is particularly vital in the biotech sector, where the path from lab to market is long and expensive. By outsourcing the capital-intensive manufacturing component to a dedicated partner, Agenus can channel its resources toward completing the pivotal BATTMAN trial and preparing its comprehensive data packages for regulatory review.

The agreement's total of up to $50 million in contingent payments is contractually allocated for production, ensuring that funds are ring-fenced for the express purpose of creating drug supply. This reassures investors that the company is executing a clear plan to bring its lead assets to market without unexpected impacts on its balance sheet from manufacturing scale-up costs.

As Agenus and Zydus begin their work, the focus now sharpens on the next series of catalysts: advancing patient enrollment in the Phase 3 trial, continuing to supply early access programs, and ultimately, submitting the applications that could make BOT and BAL a new standard of care for cancer patients with limited options.